Future Outlook of the Unresectable Hepatocellular Carcinoma Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the unresectable hepatocellular carcinoma market right now?
In recent times, a slight increase has been observed in the market size of unresectable hepatocellular carcinoma. The market is projected to rise from $1.98 billion in 2024 to $2.01 billion in 2025, following a compound annual growth rate (CAGR) of 1.9%. The growth during the historical period can be traced back to the advancements in chemotherapy, results of clinical trials, restrictions in liver transplants, an escalation in cancer cases, and wider availability of therapeutic options.
How fast Is the unresectable hepatocellular carcinoma market expected to grow, and what’s its future value?
The market size for unresectable hepatocellular carcinoma is projected to observe considerable expansion in the coming years, rising to a value of $2.95 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 10.0%. The expected growth during the forecast period is attributable to factors such as amendments in healthcare policies, implementation of patient stratification tactics, the employment of real-world evidence, promotions for patient awareness and advocacy, alongside economic dynamics. Key trends expected to be encountered during the forecast period encompass precision medicine and biomarkers, data integration and real-world evidence, multidisciplinary methodologies, international clinical trials and cooperative efforts, as well as patient-focused care.
Get your unresectable hepatocellular carcinoma market report here!
What are the leading drivers of growth in the unresectable hepatocellular carcinoma market?
The surge in liver cancer occurrence is propelling the progression of the market for unresectable hepatocellular carcinoma. When tumor cells begin to multiply uncontrollably, overtaking the liver’s healthy, functioning cells, liver cancer occurs. Unresectable hepatocellular carcinoma, a particular type of cancer, is typically combated via liver transplantation and radiofrequency ablation. As per the Journal of Hepatology, a peer-reviewed scientific journal based in Switzerland, in October 2022, liver cancer resulted in 830,200 deaths worldwide by 2020. Moreover, the forecast suggests 1.4 million new liver cancer cases will be diagnosed between 2020 and 2040, which is a 55.0% annual increase in the number of cases. Adding to this, the American Cancer Society, a non-profit organization based in the US, stated in January 2024 that they anticipate 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer in the U.S. in 2024 with an estimated 28,000 in men and 13,630 in women. About 29,840 deaths are expected, with 19,120 men and 10,720 women. Thus, the escalating liver cancer frequency is fueling the advancement of the unresectable hepatocellular carcinoma market.
What are the key segments defining the unresectable hepatocellular carcinoma market?
The unresectable hepatocellular carcinoma market covered in this report is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
Who are the key players steering the development of the unresectable hepatocellular carcinoma market?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
What emerging trends are influencing the growth of the unresectable hepatocellular carcinoma market?
The trend of product innovation is notably rising within the unresectable hepatocellular carcinoma market. To maintain their market stance, leading firms within this market are leveraging innovative products. A case in point is AstraZeneca, a pharmaceutical and biotechnology company based in the UK. In October 2022, the company introduced the FDA-approved Imjudo (tremelimumab) in conjunction with Imfinzi, specifically for unresectable liver cancer patients in the US. This innovative treatment approach, referred to as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), incorporates a solitary dose of the anti-CTLA-4 antibody Imjudo 300mg along with the anti-PD-L1 antibody Imfinzi 1500 mg at four-week intervals. The result of this combination was a 22% reduction in mortality risk compared to those administered with sorafenib.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12079
Which regions are most influential in expanding the unresectable hepatocellular carcinoma market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pain Management Devices And Therapies Global Market Report 2024
Pancreatic Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Metabolomics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
